Target intelligence / Profile preview

Class A basic helix-loop-helix protein 15 (BHLHA15)

Target
BHLHA15
Molecular classification
Transcription factor, Basic helix-loop-helix (bHLH) family protein
01

Overview

Class A basic helix-loop-helix protein 15 (BHLHA15, commonly known as MIST1) is a transcription factor encoded by the BHLHA15 gene[1][3][6]. Its protein structure allows binding to E-box DNA motifs as a homodimer or as a heterodimer with E-proteins such as E12 and E47[2][3]. MIST1 regulates the organization and identity of secretory cells in exocrine tissues such as the pancreas, salivary glands, and stomach, is critical for proper localization of organelles, and plays a role in cell-derived responses to ER stress[1][3][5]. Loss or genetic knockout of MIST1 leads to disorganization of secretory granules, increased cell stress, and heightened risk of pancreatic and liver damage, including cancer[1][5]. MIST1 expression is tightly regulated in development and can serve as a biomarker for cellular injury in metabolic and alcohol-related liver diseases[5]. There is currently no information suggesting direct pharmacological targeting or therapeutic safety concerns related to drugs interacting with MIST1.

Other names
MIST1Muscle, intestine and stomach expression 1Class B basic helix-loop-helix protein 8bHLHa15bHLHb8
02

Mechanism of action

Not applicable (no direct drug interactions reported)

03

Biological functions

Regulation of secretory cell architectureControl of acinar cell function, stability, identityMaintenance of organelle localization in exocrine cellsRegulation of cell maturation and response to endoplasmic reticulum (ER) stressSequence-specific DNA binding to E-box motifsNegative regulation of myotube differentiationCell-cell adhesion mediated by cadherin
04

Disease associations

Cancer (pancreatic susceptibility with loss of function)Liver injury and fibrosis (regulator during ER stress in hepatocytes)Potential biomarker for progression of metabolic-associated steatotic liver disease (MAFLD) and alcohol-associated liver disease (ALD)Pancreatic damage
05

Safety considerations

None reported for therapeutic targeting; loss of function increases susceptibility to injury and cancer in pancreas and liver, but no drugs or therapeutic agents are currently known to target BHLHA15/MIST1
06

Biomarkers

MIST1 expression as a marker of liver damage/fibrosis progression in MAFLD and ALDER stress-inducible expression in hepatocytes and exocrine cells

Beyond the preview

Go deeper on Class A basic helix-loop-helix protein 15 (BHLHA15).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Class A basic helix-loop-helix protein 15 (BHLHA15).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call